Moreover, the pharmacokinetics of [68Ga]PSMA-11 were characterized in terms of selectivity and specificity by simultaneously assessing the differences in the level of [68Ga]PSMA-11 uptake between PSMA-positive (22Rv1) and negative (PC3) tumors and by assessing the inhibited [68Ga]PSMA-11 uptake in the PSMA-positive (22Rv1) tumor following treatment with the PSMA-specific inhibitor 2-PMPA. Here, FOLH1 is linked to neoplasm.